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ABSTRACT

Metallothionein overexpression prolongs grafts survival in the early
phase of pancreatic islet transplantation
Xiaoyan Li

December 17, 2002

Pancreatic islet transplantation is a very promising treatment for type I diabetes.
Many clinical trials have failed due to early islet loss and immune rejection. Reactive
oxygen species (ROS) have been demonstrated to be involved in graft damage during
transplantation. Metallothionein (MT) is an inducible antioxidant protein. Prior studies in
our laboratory have shown that overexpression of MT in beta-cells reduces DNA damage
and diabetes induced by streptozotocin (STZ), which damages beta cells by generating
ROS. Therefore in this study we examined whether overexpression of MT in beta cells is
beneficial to pancreatic islet transplantation. Isolated MT transgenic and normal FVB
islets were transplanted under the kidney capsule of Balb/c mice that were treated with
STZ to induce severe diabetes. We found that diabetic mice transplanted with MT islets
maintained near normal glucose levels for 16.2 ±2.S2 days while those animals
transplanted with control islets maintained normal glucose values for only 8.36 ±1.67
days (p<0.01). To determine whether the early benefit ofMT was due to protection from
early islet loss or from immune rejection, islets were transplanted into same strain mice,
thereby free of immune rejection. Under these conditions MT islets maintained much
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higher insulin content than control islets. To assess the possible mechanism .of MT
benefit isolated FVB and MT islets were exposed to hypoxia (1 % 02, 5% C02 and 94%
N2). Compared to control islets, MT decreased cell death and reduced ROS production
during hypoxia. Moreover, after isolated islets were treated with a nitric oxide donor (Snitro-N-acetyl-penicillamine)

MT

reduced

NO

induced

cell

death.

By

immunohistochemistry in allografts of FVB and MT islets MT was found to markedly
reduce the production of nitrotyrosine. These data demonstrated that MT could prolong
graft survival in pancreatic islet transplantation.

The protective mechanism may be

reduction of ROS production or protection from ROS induced beta cell death.

v

TABLE OF CONTENTS

PAGE
ACKNOWLEDGEMENTS ............................................................ iii
ABSTRACT .............................................................................. iv
LIST OF FIGURES ...................................................................... vii
LIST OF ABBREVIATIONS .......................................................... viii
CHAPTER
I.

INTRODUCTION ...................................................... 1

II.

MATERIALS AND METHODS ..................................... 6

III.

RESULTS ............................................................... 14

IV.

DISCUSSION .......................................................... 29

REFERENCES ........................................................................... 33
CURRICULUM VITAE ................................................................ 39

VI

LIST OF FIGURES

FIGURE

PAGE

1. Islet graft under the kidney capsule one month after syngeneic
Transplantation .. , ... '" ... '" ...................... , .......... " . ......... ... 20
2. Graft survival ofFVB and HMT-l islets transplanted into diabetic
Balb/c mice .................................................................. 21
3. H&E staining and immunohistochemistry staining of nitrotyrosine
in FVB and HNT -1 allografts 6 days after transplantation ............. 22
4. Retained insulin contents in grafts of FVB and HMT -1 islets after
syngeneic transplantation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... 23
5. The MT trans gene increased cell viability during hypoxia ............... .24
6. ROS production in FVB and HMT-l islets exposed to hypoxia ......... 25
7. Representative photomicrographs ofFVB and HMT-1 islets after
SNAP treatment in vitro ...................................................... 26
8. Apoptosis and necrosis in FVB and HMT-l islets exposed to
SNAP in vitro .................................................................... 27
9. Glucose stimulated insulin secretion from FVB and HMT-1
islets exposed to SNAP in vitro ............................................. 28

Vll

LIST OF ABBREVIATIONS

BSA

bovine serum albumin

CM-H2DCFDA

5-(6)-chloromethyl-2', 7' -dichlorodihydrofluorescein
diacetate

DAB

diamino benzidine

FBS

fetal bovine serum

FRs

free radicals

HBSS

Hanks' balanced salt solution

KRBB

Krebs-Ringer bicarbonate buffer

MT

metallothionein

PNF

primary non-function

SNAP

S-nitro-N -acetyl-penicillamine

ROS

reactive oxygen species

SOD

superoxide dismutases

STZ

streptozotocin

Vlll

CHAPTER I
INTRODUCTION

Diabetes mellitus is a metabolic disorder characterized by glucose intolerance and
hyperglycemia. In the United States, between 6%-7% of population equating to about 16
million people are suffering from this disease and every year over 105 billion dollars are
spent on its treatment (Olefsky 2001). It is projected that the prevalence of diabetes in the
United States will increase to approximately 9% by 2025. Elevated blood glucose level in
diabetes is associated with an increased risk of developing microvascular diseases,
principally retinopathy, nephrophathy, and neuropathy. Due to these long-term
complications, diabetes has caused an enormous burden of morbidity. To date diabetes is
the leading cause of blindness, amputations and end-stage renal disease and the sixth
leading cause of death in the United States. But unfortunately all current drug therapies
for diabetes including intensive insulin therapy do not provide sufficiently tight control of
blood glucose to avoid the late devastating complications of this disease( 1998; 1993).
Islet transplantation has become accepted as an alternative therapy for treatment of
type 1 diabetes. Compared to whole pancreas transplantation, islet transplantation is not
only a much less invasive procedure but also a procedure much safer and less costly. It
may be possible to induce immune tolerance of the engrafted islets by pretreating them in
culture or by pretreating the recipient with donor antigen. It is also possible to use
cryopreserved pancreatic islets (Warnock et al. 1991) rather than fresh islets or whole
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pancreas which normally are very limited resources. It has been proven, that clinical islet
transplantation, when successful, is capable of maintaining excellent metabolic control in
the absence of hypoglycemia and stopping the progression of clinical long-term
complications(Boker et at. 2001). But over the years this approach has had a poor record
of accomplishment in achieving independence from exogenous insulin - approximately
12% of allotransplanted patients achieved insulin independence for over 7 days(White et

al. 2001). It has been noticed that the percentage of long term graft survival in islet
transplantation is much lower than whole-pancreas transplantation. Pancreas graft
survival for more than one year is respectively 82%, 74% and 76% when the organ was
implanted after the kidney, simultaneously with kidney, or alone while the islet graft
survival after one year is less than 10%(White et al. 2001). However a more recently
published study illustrated that islet transplantation is still a very encouraging approach
for diabetes treatment. Shapiro and his colleagues (Ryan et al. 2002) established the
Edmonton protocol. This method relied on long term application of immunosuppressors
and required more than one donor pancreas for one recipient, however this method was
more successful-80% of transplanted patients were insulin independent for more than 1
year.
The consistent achievement of long-term success in clinical islet transplantation is
limited by the islet mass that can be effectively engrafted and that can maintain function.
Two important factors: early islet loss immediately after transplantation and relatively
late-occurred immune rejection may account for the islet graft failure after islet
allotransplantation. The early events leading to graft loss are termed primary nonfunction (PNF) or early islet loss. This might be an essential determinant for the success
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of islet transplantation(Brendel et al. 1999) because a majority of islet grafts are damaged
immediately after transplantation. PNF could result from implantation of an inadequate
number of functional islets or inflammatory reactions elicited by the interaction between
the implanted islets and components of the blood stream(Bennet et al. 2000; Bennet et al.
1999) or immune components residing in the local organ (Bottino et al. 1998). This
interaction leads to generation of proinflammatory cytokines, nitric oxide and reactive
oxygen species (ROS), and thereby cytotoxic destruction to the islet graft (Davalli et al.
1996). It has been clearly demonstrated that local activation of liver macrophages(Steiner
et al. 1997; Kroncke et al. 1993) and endothelial cells (Steiner et al. 1997; Kroncke et al.

1993) can mediate PNF by releasing cytokines and nitric oxide in intraportal islet
allotransplantation. In the rat islet transplantation model, nitric oxide is considered the
main islet-toxic agent from allogeneic or syngeneic macrophages(Stevens et al. 1995). In
addition to local nonspecific inflammatory reactions, islet graft also suffers from an
initial period of hypoxic ischemia after transplantation. The engrafted islets are
essentially avascular tissue that won't have enough blood supply before the completion of
revascularization to the host· organ.
et al. 1992b).

Revascularization requires over one week (Menger

Therefore the oxygen tension within the islet graft is relatively low

(Carlsson et al. 2001c) in the early stage of islet transplantation. PNF might be initiated
by this ischemic microenviroment because ischemia followed by reperfusion is a
condition known to produce detrimental ROS in transplanted organs (Li et al. 1997;
Petrowsky et al. 1995; Land et al. 1994; Nakao et al. 1994).
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The damaging effects of ROS on pancreatic islets have been widely investigated in
diabetes (Xenos et al. 1994; Horio et al. 1994; Brenner et al. 1993; Suarez-Pinzon et al.
1997; Xu et al. 1999) as well as in islet transplantation (Stevens et al. 1996; Karsten et ai,
2001; Mendola et al. 1989), It has been shown that the exposure of isolated human
(Hadjivassiliou et al. 1998) and rodent islets(Malaisse et al. 1982d; Xu et at. 1999b;
Hadjivassiliou et al. 1998) or beta cell lines (Zhang et al. 1995) to ROS markedly inhibits
cell functions including beta cell insulin biosynthesis and secretion, or results in beta cell
apoptosis and necrosis. Pancreatic beta cells are much more susceptible to ROS
destruction than other cell types such as those in kidney and liver. The most striking
evidence is that pancreatic islets are highly sensitive to the destruction of two beta-cell
toxins, alloxan and streptotozocin (STZ). Both compounds are widely used to produce
diabetes and their relatively selective damage to beta cells is thought to act through
generation of ROS including superoxide radicals, nitric oxide radicals and hydrogen
peroxide(Grankvist et al. 1981a; Takasu et al. 1991). Some other studies also proved that
pancreatic beta cells have several times higher sensitivity than kidney, muscle, or liver
cells to the damage of superoxide radical (Burkart et al. 1992), hydrogen peroxide
(Brunk et al. 1995) and nitric oxide (Eizirik et al. 1994). Further, quantitative studies of
ROS scavengers in pancreatic beta cells indicate that the sensitivity of islets is due to
inadequacy of ROS detoxifying systems. Compared with liver, the total islet superoxide
dismutases (SOD) is less than 30% (Grankvist et at. 1981 b). Glutathione peroxidase and
catalase in the beta cell are less than 2% of liver(Grankvist et al. 1981 b; Welsh et ai,
1995; Malaisse et ai, 1982; Johansson & Borg 1988). This deficit of ROS detoxifying
systems may contribute significantly to the deterioration of islet cells in type 1 diabetes
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and probably to the islet graft loss after transplantation. Recent data have shown the
successful improvement of early islet transplant survival by various antioxidant
combinations such as a-tocopherol (Burkart et at. 1995) and other vitamins(Winter et at.
2002). Consequently we hypothesize that increasing ROS defenses specifically in beta
cells may benefit islet transplantation.
To test our hypothesis, we selected metallothionein (MT) as our candidate
antioxidant because MT is an efficient ROS scavenger. MT is a cysteine-rich protein
involved in zinc homeostasis and metal detoxification(Klaassen & Liu 1997). MT also
appears to play important roles in ROS protection. MT has been shown to be an
extraordinarily efficient ROS scavenger protecting from hydroxyl radicals(Malaisse et al.
1982; Schnedl et ai. 1994), nitric oxide radicals (Schwarz et al. 1995) and superoxide
radicals(Rocic et al. 1997; Kumari et al. 1998; Schwarz et al. 1995). MT protects against
many agents known to act through ROS, including hydrogen peroxide, radiation,
glutathione depletors, adriamycin, and xanthine oxidase(Sato & Bremner 1993). By using
this molecule, we have produced two lines of transgenic mice with overexpression of MT
in pancreatic beta cells on the FVB mouse strain. We found that the MT trans gene had no
deleterious effect on beta cell structure or function. But overexpression of MT was very
effective in protecting FVB mice from diabetes induced by streptozotocin (Chen et al.
2001). Therefore in the present study we are further testing the potential effect of MT on
islet transplantation. We want to know whether an increased ROS defense system in beta
cells is beneficial for graft survival in islet transplantation.
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CHAPTER II
MATERIALS and METHODS

Animals
Transgenic mice were established on FVB mice with the overexpression of human
MT II gene by standard transgenic techniques. This transgene was specifically expressed
in pancreatic beta cells because it was driven by a human insulin promoter. The
transgenic mice or islets were designated as HMT-1 and the control FVB mice or islets
were designated as FVB.

Chemicals
Streptozotocin, collagenase (type V), Histopaque 1077 and metallothionein were
obtained from Sigma (S1. Louis, MO). Hank's balanced salt solution (HBSS), RPMI 1640
medium, and fetal bovine serum (FBS) were supplied by Gibco BRL (Rockville, MD). .
Rat insulin standard was bought from Linco (S1. Charles, MO). Rabbit antiserum to
guinea pig insulin, was purchased from BioGenex (San Ramon, CA). Monoclonal antiNitrotyrosine antibody was supplied by Cayman (Ann Arbor, MI). 5-(6)-chloromethyl2', 7' -dichlorodihydrofluorescein diacetate (CM-H2DCFDA) was purchased from
Molecular Probes (Eugene,

OR).

Alarmablue was purchased from

International (Camarillo, CA).
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Biosource

The isolation procedure was based on a modification of the method of Gotoh et al
(Gotoh et al. 1985). Mice were anesthetized with avertin at the dose of 6mg/g body
weight via intraperitoneal injection. The pancreas was inflated with 3 ml of 1.55 mg/ml
collagenase Type V and incubated at 37°C for 20 min. The digest was resuspended in 10
mL Histopaque 1077, overlaid with 10 ml of HBSS and centrifuged at 700 x g for 20 min
at 10°C. Most of the gradient, excluding the pellet was collected and washed 3 times
with cold HBSS. Islets were then handpicked in RPMI 1640 medium supplemented with
10 % fetal bovine serum and 100 V/ml penicillin and 100 Ilg/ml streptomycin. Islets were
maintained in suspension culture in RPMI 1640 medium at 37°C and 5 % CO 2•

Allotransplantation
400 FVB or HMT-1 islets were transplanted under both kidney capsules (200
each) according to a modification of the procedure of Montana et al (Montana et al.
1993b). Recipient mice were male Balb/c mice purchased from Jackson Laboratory (Bar
Harbor, Maine). The Balb/c mice, at the age between 8-12 weeks, were injected with STZ
(ip. 220mg/kg) for 1 to 3 days to induce diabetes. Only the mice with blood glucose range
from 350mg/dl to 500mgldl were selected as recipients for following transplantation
surgery. After recipient mice were anesthetized via ip. injection with 10 ul/g of a solution
containing 10 mg/ml ketamine and 3.2 mg/ml xylazine, the left side mouse kidney was
first externalized through a small incision and kept moist with saline. An incision was
made near the posterior pole of the kidney. 200 islets were picked into a gel-loading
pipette tip (0.5 mm diameter) mounted on a l-cc Hamilton syringe (Reno, NV, VSA) and
allowed to settle. The tip was inserted through an incision beneath the kidney capsule and
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the islets were gently forced out of the tip. The body wall and the skin were closed with
sutures. Then the transplantation to the right side kidney was performed by the same
procedure. After transplantation, the tail blood glucose levels of the transplanted mice
were monitored every other day. Graft failure was defined as a return of hyperglycemia
(blood glucose> 250 mg/dl) on two consecutive measurements. Grafts in some recipients
were recovered 5 days after transplantation and sectioned for H&E and nitrotyrosine
staining.

Syngeneic transplantation
50 FVB and HMT-1 islets were transplanted separately under each kidney capsule
in a same normal FVB mouse. 6 days later, grafts were recovered and homogenized in
acid ethanol (23 ethanol: 2 HCI: 75 H20, v/v/v) for insulin extraction. The preserved
insulin content in the islet grafts was measured by an anti-insulin antibody coated tube
RIA kit (Diagnostic Products) and rat insulin standard.

Immunohistochemistry for nitrotyrosine and insulin
Islet graft was fixed in 10% formaldehyde in 0.1 molll phosphate buffer (pH 7.2),
dehydrated in an ascending graded series of ethanol, and subsequently infiltrated with
paraffin. Serial section were cut at 5 Ilm, mounted on polylysine-coated slides, and then
deparaffinized in xylenes and a descending graded series of ethanol. For nitrotyrosine
staining, slides were treated with target retrieval solution (Dako corporation), followed by
M.O.M mouse Ig blocking regent (Vector Laboratories). Nitrotyrosine monoclonal
antibody (Cayman) was added on the slides at the concentration of 10 Ilg/ml and
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incubated overnight at room temperature. After 3 washes in phosphate-buffered saline,
slides were incubated with the biotinylated anti-mouse IgG reagent, followed by ABC
reagent and developed with DAB as chromagen. The slides without primary antibody
treatment were used as negative control.
For insulin staining, sections were treated with rabbit anti-guinea pIg insulin
antibody diluted I to 100 and incubated for 90 min at 37°C. After 4 washes in phosphate
buffered saline, slides were incubated with the appropriate biotin-labeled second antibody
followed by peroxidase labeled streptavidin and developed with DAB as chromagen.

Hyooxia in vitro studies
Isolated FVB and HMT-l islets were cultured in a 96-well plate placed in a sealed
hypoxic chamber saturated with 1% 02, 5% C02 and 94% N2 for 24h, 48h, and 72h
respectively. Cell viability was assessed by measuring islet metabolism as indicated by
alamar blue absorbance. The data for cell viability were represented as percentages of the
viabilities of control cells which were cultured under normal condition. ROS production
in islets after hypoxia 2 or 7 hr was measured with fluorescence dye (CM-H2DCFDA)
(Molecular

Probes).

Islets

treated

with

24h

hypoxia

were

picked

for

immunohistochemistry for insulin and nitrotyrosine.

Nitric oxide in vitro studies
Isolated FVB and HMT -1 islets were exposed to different concentrations of a nitric
oxide donor, S-nitro-N-acetyl-penicillamine (SNAP). Glucose stimulated insulin
secretion was tested by static assay on 96-well tissue culture microplates and insulin
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levels were measured with anti-insulin antibody coated RIA kit. Apoptotic and necrotic
DNA were detected by an anti-histone biotin/anti-DNA POD ELISAplus kit (Roche). All
values were normalized to islet total DNA measured with picogreen DNA quantification
kit (Molecular Probes).

Assays of insulin secretion. insulin content and DNA content
Insulin secretion was measured by static assay on 96-well tissue-culture
microplates. For each well 6-10 islets were hand picked into modified KRB (KrebsRinger bicarbonate buffer containing the designated concentration of glucose and
supplemented with 10mM Hepes, pH 7.4 and 0.1% BSA) containing 3 mM glucose at
37°C. After two washes in 3 mM glucose KRB the islets were incubated for consecutive
30 min incubations in 3 and 20 mM glucose KRB. To determine islet insulin content,
islets were sonicated in 150

~l

lOmM Tris HCI, ImM EDTA, Img/ml RIA grade BSA,

pH 7.0 for 30 seconds. Fifty

~l

of the solution was used to extract islet insulin with 100

~l

acid ethanol (75 ethanol / 2 concentrated HCI / 23 H20, v/v/v) at 4 °C overnight. The

remainder of the sonicate was digested with an equal volume of 200

~g/ml

proteinase K

in 100 mM Tris HCl, pH 8.5, 5 mM EDTA, 0.2 % SDS at 55°C for 2 hours and used for
islet DNA quantification with picogreen using a kit from Molecular Probes. Insulin was
measured with the coated tube RIA kit from Diagnostic Products and rat insulin
standards.
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Islet fluorescence measurement of ROS
Both hypoxia treated or untreated islets were loaded with 1 ~M 5-(6)-chloromethyl2', 7' -dichlorodihydrofluorescein diacetate (CM-H2DCFDA) (Molecular Probes, Eugene,
OR) for 30 min. After islets were washed, fluorescence intensity of each islet was
measured using an excitation wavelength of 485 nm and an emission wavelength of 530
nm. Each islet in different groups was sampled using an Olympus IX70 inverted
microscope equipped with a digital cooled CCD camera and ImagePro image analysis
software (Media Cybernetics, Silver Spring, MD) under same parameters. Fluorescence
was calibrated using Image-Pro Plus software.

Alamarblue assay
Alamarblue assay, which incorporates a redox indicator that changes color or
fluorescence in response to cell metabolic activity, is a commonly used method to assess
cell viability and/or proliferation of mammalian cells(Gonzalez & Tarloff 2001) and
micro-organisms(Byth et al. 2001). In our studies, 15 overnight cultured islets either
control FVB islets or transgenic HMT-1 islets were hand picked into 200ul fresh culture
medium containing 1:20 diluted AlamarBlue on a 96-well plate. Islets were cultured for
4hr and the developed AlamarBlue absorbance was measured on a fluorescent microplate
reader (Tecan) at the excitation wavelength of 535nm and the emission wavelength of
595nm. After three washes of 200ul fresh culture medium, islets were cultured and
treated under different oxygen conditions for specified times. At the end of treatment, the
culture medium was replaced with new 200ul fresh culture medium containing 1:20
diluted Alamarblue. The color was developed for another 4hr and the absorbance was
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measured again. The islet cell viability was calculated from the ratio of the absorbance
value after treatment over the absorbance value before treatment.

Apoptotic and Necrotic DNA measurement
The measurement of apoptotic and necrotic DNA in SNAP treated islets was
performed by a cell death detection ELISA (Roche) based on the manufacturer
instruction manual. Basically, 40 to 50 islets were cultured in 500ul fresh culture medium
in a 1.5ml microtube with or without SNAP treatment for 24hrs. After treatment the
microtube was centrifuge at 200g for 10 minutes at 4°C. The supernatant was removed as
the necrosis DNA sample. The pellet was lysed by 1OOllllysis buffer from the kit for 30
minutes at room temperature. The microtube was centrifuge again at 200g for lO minutes
at 4°C. The supernant was removed as apoptotic DNA sample. To quantify the necrotic
and apoptotic DNA, both DNA samples were added to the streptavidin-coated microplate
offered in the kit. With the addition of a mixture of anti-histone-biotin and peroxidaseconjugated anti-DNA antibody followed by 2hrs incubation at room temperature, the
DNA samples were captured to the microplate by biotinylation. After washing off
unbound components, the quantitative determination of sample DNA content was carried
out by measuring conjugated peroxidase activity with ABTS as substrate at 405nm.

Data analysis
Data are presented as the mean ± standard error. Statistical significance for twogroup analysis was performed by student's t-test (2-tailed) and for three group analysis
was performed by ANOVA and Dunnet's post hoc (2-tailed) test. Kaplan-Meier survival
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analysis and Mantel-Cox Log-rank test were used to analyze islet graft survival time.
Computations were done using the statistical program from SPSS (version 10.0).
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CHAPTER III
RESULTS

Transplantation
Islet transplantation has been carried in many different sites in recipients, such as
liver intraportal route, kidney subcapsular site, intraperitoneal spice and small bowel
subserosal space. In our studies we successfully set up a transplantation method by
placing the islet graft under kidney capsule. This site is optimal for islet survival in that
the site beneath the kidney capsule is expected to have sufficient blood supply but have
less direct interactions with immune system than liver intraportal site does(Brandhorst et
al. 2001). As shown in Figure 1, the isolated islets from FVB mouse were implanted

under FVB mouse kidney capsule. Thirty days after transplantation, we recovered the
islet graft and examined the islet morphology and insulin content by H&E staining and
immunohistochemistry. We found that the 30-day islet graft still maintained relatively
normal islet structure and insulin staining.
To test whether overexpression of MT in the beta cells would improve islet graft
survival, we first performed an allotransplantation (allotransplantation indicates that the
grafts were transplanted on to a different strain of mice) study by implanting 400 FVB
control islets or MT transgenic islets under the renal capsule of STZ induced diabetic
Balb/c mice. We found that the Balb/c diabetic mice that received a graft of 400 FVB
islets were brought to euglycemia for a short period of time. However, within about one
week they returned to hyperglycemia. The average period of euglycemia with an FVB
14

islet graft was 8.36±1.67 days. However, the Balb/c mice that received MT transgenic
islet grafts remained euglycemic for a much longer time. The period of euglycemia for
recipients of an MT islet graft is markedly increased to 16.2 ±2.S2 days (Figure 2). We
also examined nitrotyrosine staining in both MT and FVB islet grafts recovered after 5
days of transplantation. Nitrotyrosine is recognized as an indicator of protein oxidative
damage when the tyrosine residues are oxidized by peroxynitrite, a highly potent ROS
formed by superoxide radical and nitric oxide. In transplantation the production of
peroxynitrite was greatly increased in the grafts suggesting that peroxynitrite may play an
important role in graft rejection and loss (MacMillan-Crow et al. 1996). Our data
confirmed this finding. In Figure 3, the nitrotyrosine staining in control FVB islet graft
was marked elevated after transplantation. But the antioxidant MT transgene markedly
reduced the nitrotyrosine production. These data indicate that ROS may be involved in
the graft damage, at least in the early stage of allotransplantation and the protective effect
of MT to prolong islet graft survival may be through the elimination of oxidative damage
by scavenging ROS.
During allotransplantation the islet grafts are exposed to an environment
containing a variety of stressors, including immune rejection, glucose toxicity, ischemic
damage and reperfusion injury. All these processes can induce ROS production. In order
to differentiate whether the early benefit of the MT transgene is due to the protection
against ischemic/reperfusion injury or against immune rejection or glucotoxicity, we did
further syngeneic transplantation studies. In this transplantation model we used FVB
mice with normal blood glucose levels as recipients, thereby excluding the influence of
immune rejection and glucose toxicity. Six days after transplantation islet graft was

15

removed from the kidney and the graft insulin content was measured. Graft insulin
content is a widely used parameter to assess the response of transplanted islets(Montana
et al. 1993; Jansson et al. 1995). As shown in Figure 4, both FVB and MT islet grafts

after 6 days of syngeneic transplantation lost part of their insulin contents compared to
their initial values. However, FVB grafts lost much more insulin than MT islet grafts did.
MT overexpression protected beta cells by preserving more than 50% of original islet
insulin, whereas FVB graft lost almost 80% of original insulin. This finding that islet
grafts lose insulin very much in the early stages of syngeneic transplantation is consistent
with other reports(Davalli et al. 1996; Xu et al. 1999).

During this early stage of

transplantation, the islet cells in the graft dynamically change their metabolism rate and
gene expression pattern characterized by substantial islet cell dysfunction and death.
Ischemia after the transplantation and the following reperfusion during revascularization
may contribute to this early islet graft failure. Our result that MT protected from early
islet graft insulin loss indicates that the MT transgene may protect from
ischemialreperfusion damage after transplantation. This is because ischemia followed by
reperfusion is known to induce ROS and antioxidants are known to be beneficial for
preventing reperfusion injury(Li et al. 1997; Wang et al. 2001).

Hypoxia in vitro studies
To assess the possible mechanism of MT protection, we carried out in vitro
studies by exposing isolated FVB and MT islets to hypoxic conditions in a sealed
chamber. In this chamber only 1% O2 was included, which is close to the environment
that the transplanted islets suffer from in the in vivo condition after transplantation. We
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chose 1% 02 because Carlsson et al. (Carlsson et al. 2001) recently reported a mean P02
level was 5-10 mmHg (about 1% 02) in syngeneically transplanted islets. After exposure
to the hypoxia condition for 24, 48, and 72hrs, the cell viability of both FVB and MT
islets was measured with Alamar Blue assay. As shown in Figure 5, the islet cell viability
in FVB islets was markedly decreased by hypoxia treatment. However the overexpression
of MT in beta cells significantly inhibited hypoxia induced reduction of cell viability at
all time points we analyzed.
Hypoxia and hypoxia followed by reoxygenation is known to induce ROS
production(Li & Jackson 2002; Duranteau et al. 1998). Therefore it may also be true that
overexpression of the ROS scavenger, MT, would decrease hypoxia induced ROS
production in the islet cells. We measured ROS production by a redox state sensitive
fluorescence dye (CM-H2DCFDA) in both FVB and MT islets treated with hypoxia for 2
and 7 hr. The data in the Figure 6 demonstrated that hypoxia induced ROS generation in
both FVB and MT islets. But the ROS levels in MT islets were dramatically lowered by
the MT trans gene. Hence, the protective effect of MT against hypoxia induced cell
damage may be through a decrease of ROS production.

Nitric oxide in vitro studies
The association between NO production and early islet graft damage has been
previously described in xenotransplantation(Ketchum et al. 2000). Application of
selective iNOS inhibitors has been shown to protect from early islet graft failure in rat
intraportal islet transplantion(Brandhorst et al. 2001). Our immunohistochemistry data of
nitrotyrosine staining in allotransplantation study support this concept. Our results
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suggest that NO may be one of the major ROS involved in the early islet graft damage
after transplantation and NO perhaps is one of the main targets that MT acts on. By
eliminating the toxic effects of NO, MT is then able to provide protective effect against
early islet graft destruction. Therefore, to test this hypothesis both FVB and MT islets
were treated in vitro with a NO donor, SNAP at different concentrations. After treatment
we analyzed the islet cell viability by observing islet morphology and by measuring
apoptotic and necrotic islet DNA. We also evaluated the islet function by measuring
glucose stimulated insulin secretion.
Visual observation revealed obvious, reproducible differences in the sensitivity of
MT and FVB islets (Figure 7) to SNAP. FVB islets were visibly damaged at 1 mM
SNAP and generally disintegrated into single cells at 2 and 3 mM. But MT islets did not
exhibit a similar degree of damage until the SNAP concentration was raised to 3 mM.
The apoptotic and necrotic DNA quantification by a photometric enzyme-immunoassay
confirmed this protective effect of MT. As shown in Figure 8, SNAP treatment induced
islet DNA cleavage. Both apoptotic DNA and necrotic DNA were greatly increased in
FVB control islets after exposure to SNAP. However MT islets had markedly reduced
contents of cleaved DNA, relative to FVB islets. This was especially obvious at 3mM
SNAP. At this concentration DNA damage in the transgenic MT islets was over 50%
less than that in FVB control islets. These results imply that one mechanism of preserved
islet mass by the MT transgene was probably through the protection of islet DNA.
However further analysis of islet insulin secretion function failed to confirm this
protective effect of MT. In Figure 9 we exposed both FVB and MT islets to different
concentrations of SNAP for 12 hrs, and the glucose stimulated insulin secretion was
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measured. We found SNAP significantly inhibited insulin secretion on both types of
islets. But no difference in insulin secretion was found between FVB and MT islets.
Currently we have no good explanation for the discrepancy that MT protected from
SNAP induced islet DNA damage but not from the inhibition of islet insulin secretion. It
is very possible that these two effects on islet cells may be through two different
pathways and MT only has an action on one of them. It is notable that the insulin
secretion of FVB islets significantly rose at 2 mM SNAP. Since the increase in released
insulin was seen at both low and high glucose concentrations this was probably not due to
regulated insulin secretion. This phenomenon might be explained by the fact that at
2mM SNAP structural integrity of FVB islets was severely damaged (Figure 7). Due to
this structural damage, beta cell insulin leaked into the media.
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Figure 1. Islet graft under the kidney capsule one month after syngeneic transplantation.
In panel A, the white spot is the graft of FVB islets transplanted to FVB recipient mouse.
Panel B is H&E staining of the graft. Panel C is insulin staining of the graft (Brown
staining). Arrows in each panel point to the graft.
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Figure 2. Graft survival ofFVB and HMT-l islets transplanted into diabetic Balb/c mice.
MT overexpression prolongs islet graft survival in allotransplantation. 400 islets were
transplanted under both kidney capsules of STZ induced diabetic Balb/c mice. Graft
survival was defined in Methods. The survival time ofHMT-l grafts (16.2 ±2.S2 days) is
significantly longer than that ofFVB grafts (8.36 ±l.67 days), P<O.Ol by Mantel-Cox
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HMT-1 allografts 6 days after transplantation. MT overexpression reduced nitrotyrosine
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Figure 4. Retained insulin contents in grafts of FVB and HMT-1 islets after syngeneic
transplantation. MT overexpression protects from graft insulin loss during syngeneic
transplantation. Islets were transplanted into normal FVB mice and the recovered graft
insulin levels were measured as described in Methods. Data at 6 days was collected from
12 recipient FVB mice. The value of MT graft is different from the value of FVB graft,

*

P<O.Ol by two tailed Student's t-test. Vertical bars indicate standard error of mean.
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of SNAP are shown on the left. Similar results were obtained in four independent
experiments. Magnification X 100.
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stimulated insulin secretions were measured as described in Methods. Data were
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islet structural integrity, as seen in Fig 7.
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CHAPTER IV
DISCUSSION

In this study, we explored the effect of overexpression MT in beta cells on the
outcome of islet transplantation. We demonstrated that MT overexpression could prolong
graft survival time. The benefit of MT is probably due to the protection from early islet
graft damage not immune rejection. In addition, a set of in vitro experiments was
performed to reveal the possible mechanisms of MT protection. Hypoxia in vitro studies
demonstrated that MT could inhibit hypoxia induced beta cell death and ROS production.
Further, nitric oxide in vitro studies suggested that islets that overexpressed MT were
more resistant to nitric oxide induced cytotoxicity, but MT overexpression could not
protect from nitric oxide induced insulin secretion dysfunction.
Although the data we presented here only showed that MT doubled islet graft
survival time in allotransplantation, the result could still be significant for clinic trials of
islet transplantation. To date islet transplantation has been recognized as a very valuable
therapy for treatment of type 1 diabetes. Despite a fairly low number of successful
procedures, when successful, the islet transplantation is able to tightly control blood
glucose level without insulin therapy and stops deleterious long-term complications.
However many clinical trials of islet autotransplantation have demonstrated that islet
grafts fail very soon, usually in the subsequent weeks and months after a short period of
euglycemia immediately after surgery (White et al. 1998; Farney et al. 1991; Cameron et
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al. 1980). Since there is no immune rejection during islet autotransplantation, these data

indicate that the early phase of transplantation might be an important stage for late islet
engraftment and normal beta cell function. In this stage islet grafts are destroyed by many
cytotoxic mediators including local activated macrophage, cytokines, nitric oxide and
ROS. Therefore the early stage of islet graft loss after transplantation might be one of the
main obstacles for the success of islet transplantation. Looking for approaches to
overcome this obstacle should be a promising direction of islet transplantation study. In
our present study, the finding that MT significantly improved islet graft survival both in
allotransplantation and syngeneic transplantation may indicate that this procedure could
provide a feasible method to increase the chance of successful islet transplantation.
Understanding the mechanism of the early graft loss is another important step in
islet transplantation study. This mechanism could be very complex because after
transplantation many factors have been shown to be involved in this process of damage.
This loss is unlikely due to immune rejection because this specific immune reaction
won't occur normally until two weeks after transplantaion. Therefore, other factors may
account for the early islet graft damage in our allotransplantation.
After transplantation the islet graft is under a condition of oxidative stress.
Chronic hypoxia and ischemialreperfusion are among the reasons leading to this
oxidative damage. It has been measured that the mean POz is 5-10 mmHg (about 1% 02)
in syngeneically transplanted islets 9-12 weeks after implantation, regardless of the
implantation site(Carlsson et al. 2001). Islet grafts are initially an essentially avascular
tissue. They are particularly prone to the destruction caused by ischemia followed by
reperfusion during the process of revas cuIarization of the islet grafts(Menger et al. 1992).
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Low levels of oxygen or a hypoxic environment can impair islet cell function for example
by inhibiting beta cell insulin biosynthesis. It has been shown that there is a strong
correlation between reduced oxygen supply and the occurrence of apoptosis in isolated
human and rat islets(Moritz et al. 2002). The hypoxia in vitro study in the present study
also demonstrated this point.
It has been well documented that various ROS including nitric oxide(Reid et al.

2001) and superoxide(Akizuki et al. 2000) are produced during the early phase of
transplantation. Both chronic hypoxia, the ischemiafreperfusion process (Li & Jackson
2002)and the non-specific infiltration of macrophage in the islet graft may contribute to
ROS generation in the early stages of islet transplantation. Systemic measurement of
nitrotyrosine production after transplantation indicates that the day for the peak of
nitrotyrosine production is 7 days after transplantation(Sakurai et al. 1999). Our data
confirmed these concepts by detecting the ROS production under hypoxia condition and
by immunostaining of nitrotyrosine in the allotransplanted graft. Consequently ROS
mediated destruction may be another important factor in the early islet graft loss.
The pancreatic beta cells contain low levels of ROS scavenger systems(Grankvist

et al. 1981b; Welsh et al. 1995; Malaisse et al. 1982; Johansson & Borg 1988), therefore
any approach to reduce oxidative tension in transplanted islet by enhancing their ROS
defense system is expected to improve islet graft survival. In our study we introduced an
antioxidant MT transgene specifically in beta cells to increase their ROS scavenging
capacity. Our results supported the importance of antioxidants and oxidative stress in
transplantation. These data are consistent with clinical antioxidant trials and recent
successful reports of antioxidant treatments in islet transplantation(Winter et al. 2002;
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Bottino et al. 2002). In a very recent study(Bottino et al. 2002) an antioxidant SOD
mimic was found to greatly increase islet graft survival when this drug was used during
the isolation of islets. Consequently external application of antioxidants, either by direct
exposure or gene transfer into isolated islets, might be a very valuable tool to increase the
efficacy of islet transplantation.
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